X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-04-11 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.80 | +20,000 | 1,098,460 | +2% | +$16,000 | ||||||
| D | 2025-04-09 | KROS | Keros Therapeutics, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $10.13 | +934,258 | 5,390,964 | +21% | +$9,464,512 | |||||
| M | 2025-04-09 | OSTX | Os Therapies Inc | Auerbach Shalom | 10% | S - Sale | $1.36 | -60,012 | 2,769,570 | -2% | -$81,566 | |||||
| M | 2025-04-09 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $10.87 | -141,122 | 3,921,255 | -3% | -$1,533,337 | |||||
2025-04-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $35.23 | -30,000 | 624,324 | -5% | -$1,056,780 | ||||||
| M | 2025-04-09 | RNAC | Cartesian Therapeutics, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $10.21 | +149,075 | 9,630,893 | +2% | +$1,522,517 | |||||
2025-04-09 | KALV | Kalvista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners Iii, L.P. | 10% | P - Purchase | $9.42 | +25,000 | 5,303,985 | 0% | +$235,500 | ||||||
2025-04-10 | GOVX | Geovax Labs, Inc. | Spencer John N Jr | Dir | P - Purchase | $0.98 | +10,000 | 11,402 | +713% | +$9,800 | ||||||
2025-04-09 | PVLA | Palvella Therapeutics, Inc. | Jenkins George M | Dir | P - Purchase | $20.20 | +4,990 | 196,687 | +3% | +$100,797 | ||||||
| M | 2025-04-08 | RNXT | Renovorx, Inc. | Kocak Ron | VP Controller, PAO | P - Purchase | $0.79 | +12,595 | 12,595 | New | +$10,011 | |||||
| D | 2025-04-07 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $35.88 | -6,250 | 169,721 | -4% | -$224,262 | |||||
2025-04-10 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $36.77 | -5,000 | 426,795 | -1% | -$183,850 | ||||||
| D | 2025-04-08 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $60.14 | -20,760 | 19,209 | -52% | -$1,248,490 | |||||
2025-04-08 | RYTM | Rhythm Pharmaceuticals, Inc. | Mazabraud Yann | EVP, Head of International | S - Sale | $60.99 | -17,750 | 22,620 | -44% | -$1,082,497 | ||||||
2025-04-10 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.36 | +125,000 | 247,697,576 | 0% | +$169,713 | ||||||
2025-04-09 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.81 | +30,000 | 1,078,460 | +3% | +$24,399 | ||||||
| M | 2025-04-09 | TXMD | Therapeuticsmd, Inc. | Walker Marlan D | CEO | P - Purchase | $0.87 | +2,303 | 73,149 | +3% | +$1,994 | |||||
| M | 2025-04-08 | ACUT | Accustem Sciences Inc. | Cerrone Gabriele M | Dir, 10% | P - Purchase | $0.67 | +38,000 | 4,910,759 | +1% | +$25,285 | |||||
2025-04-09 | RCKT | Rocket Pharmaceuticals, Inc. | Patel Kinnari | See Remarks | P - Purchase | $4.70 | +21,099 | 575,804 | +4% | +$99,165 | ||||||
| D | 2025-04-10 | AGIO | Agios Pharmaceuticals, Inc. | Fouse Jacqualyn A | Dir | S - Sale+OE | $25.90 | -7,497 | 149,220 | -5% | -$194,172 | |||||
2025-04-10 | GOVX | Geovax Labs, Inc. | Sharkey John W. | VP, Business Development | P - Purchase | $0.99 | +6,000 | 6,191 | >999% | +$5,940 | ||||||
2025-04-08 | MBX | Mbx Biosciences, Inc. | Pescovitz Ora H. | Dir | P - Purchase | $5.89 | +7,693 | 24,329 | +46% | +$45,312 | ||||||
2025-04-09 | RNXT | Renovorx, Inc. | Bagai Shaun | CEO | P - Purchase | $0.83 | +10,000 | 312,540 | +3% | +$8,300 | ||||||
2025-04-08 | RNXT | Renovorx, Inc. | Marton Laurence | Dir | P - Purchase | $0.85 | +12,050 | 45,684 | +36% | +$10,218 | ||||||
2025-04-07 | XOMA | Xoma Royalty Corp | Sitko Bradley | Chief Investment Officer | P - Purchase | $24.70 | +2,000 | 21,403 | +10% | +$49,400 | ||||||
2025-04-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $18.04 | -6,667 | 316,643 | -2% | -$120,269 | ||||||
2025-04-08 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.84 | +26,000 | 1,048,460 | +3% | +$21,840 | ||||||
2025-04-08 | PEPG | Pepgen Inc. | McArthur James G | Pres, CEO | P - Purchase | $1.15 | +41,500 | 103,913 | +66% | +$47,725 | ||||||
2025-04-04 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% | P - Purchase | $0.42 | +60,000 | 126,744,448 | 0% | +$25,158 | ||||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Garnett Keithly | CFO | S - Sale+OE | $24.85 | -6,616 | 321,284 | -2% | -$164,426 | |||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Dir | S - Sale+OE | $24.85 | -38,464 | 6,802,224 | -1% | -$955,941 | |||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Walters Patrick | COO | S - Sale+OE | $24.85 | -11,847 | 876,373 | -1% | -$294,432 | |||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Chiang Ming-Fu (Alan) | Dir | S - Sale+OE | $24.85 | -57,696 | 2,180,049 | -3% | -$1,433,912 | |||||
| AD | 2025-03-26 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CEO, 10% | S - Sale+OE | $24.85 | -39,233 | 4,843,191 | -1% | -$975,055 | |||||
| M | 2025-04-04 | NUVB | Nuvation Bio Inc. | Hung David | Pres, CEO, 10% | P - Purchase | $1.64 | +500,000 | 58,781,054 | +1% | +$820,220 | |||||
| D | 2025-04-08 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $14.82 | -2,708 | 59,456 | -4% | -$40,133 | |||||
| D | 2025-04-08 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $14.82 | -1,028 | 22,257 | -4% | -$15,235 | |||||
| D | 2025-04-04 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $4.59 | -41,666 | 1,640,951 | -2% | -$191,151 | |||||
| A | 2025-03-31 | VKTX | Viking Therapeutics, Inc. | Rouan Sarah Kathryn | Dir | P - Purchase | $24.15 | +1,240 | 1,240 | New | +$29,943 | |||||
| D | 2025-04-08 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $36.18 | -2,000 | 140,255 | -1% | -$72,360 | |||||
2025-04-08 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.48 | +125,000 | 247,572,576 | 0% | +$184,650 | ||||||
| M | 2025-04-04 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $2.94 | -874 | 3,682 | -19% | -$2,570 | |||||
| M | 2025-04-04 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $2.94 | -3,122 | 13,209 | -19% | -$9,178 | |||||
2025-04-07 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $4.55 | -3,678 | 91,779 | -4% | -$16,740 | ||||||
| D | 2025-04-07 | SPRY | Ars Pharmaceuticals, Inc. | Shawver Laura | Dir | S - Sale+OE | $12.30 | -50,002 | 210,346 | -19% | -$615,075 | |||||
| D | 2025-04-07 | UTHR | United Therapeutics Corp | Dwek Raymond | Dir | S - Sale+OE | $284.55 | -4,000 | 1,750 | -70% | -$1,138,200 | |||||
| M | 2025-03-18 | ACUT | Accustem Sciences Inc. | Cerrone Gabriele M | Dir, 10% | P - Purchase | $0.51 | +152,802 | 4,872,759 | +3% | +$78,291 | |||||
2025-04-04 | RCKT | Rocket Pharmaceuticals, Inc. | Ondrey Aaron | CFO | S - Sale | $5.29 | -7,489 | 129,650 | -5% | -$39,647 | ||||||
2025-04-07 | RNXT | Renovorx, Inc. | Bagai Shaun | CEO | P - Purchase | $0.83 | +10,000 | 302,540 | +3% | +$8,300 | ||||||
2025-04-07 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.10 | +3,600 | 5,561,602 | 0% | +$32,760 | ||||||
2025-04-03 | ALDX | Aldeyra Therapeutics, Inc. | Perceptive Advisors LLC | 10% | S - Sale | $1.42 | -3,400,000 | 5,875,851 | -37% | -$4,828,000 | ||||||
| M | 2025-04-03 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $11.42 | +317,208 | 17,699,774 | +2% | +$3,623,970 | |||||
2025-04-03 | IBO | Impact Biomedical Inc. | Chan Heng Fai Ambrose | Dir | S - Sale | $0.50 | -351,555 | 0 | -100% | -$174,020 | ||||||
2025-04-07 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $35.78 | -2,886 | 64,689 | -4% | -$103,261 | ||||||
2025-04-04 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Pres, CEO | S - Sale | $3.74 | -245 | 82,739 | 0% | -$916 | ||||||
| D | 2025-04-04 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale+OE | $33.11 | -3,354 | 67,345 | -5% | -$111,044 | |||||
| D | 2025-04-04 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $33.11 | -1,874 | 30,375 | -6% | -$62,044 | |||||
| D | 2025-04-04 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $33.11 | -2,945 | 479,851 | -1% | -$97,503 | |||||
| D | 2025-04-04 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $33.11 | -924 | 27,047 | -3% | -$30,592 | |||||
| D | 2025-04-04 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale+OE | $33.11 | -3,029 | 45,178 | -6% | -$100,284 | |||||
| M | 2025-04-03 | XOMA | Xoma Royalty Corp | Limber Joseph M | Dir | P - Purchase | $25.34 | +30,000 | 36,208 | +483% | +$760,145 | |||||
| D | 2025-04-03 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $306.18 | -11,000 | 36,781 | -23% | -$3,367,984 | |||||
2025-04-04 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.73 | +5,500 | 5,558,002 | 0% | +$48,015 | ||||||
2025-04-03 | EWTX | Edgewise Therapeutics, Inc. | Thompson Peter A. | Dir, 10% | P - Purchase | $20.13 | +496,771 | 443,792 | -938% | +$10,000,000 | ||||||
2025-04-03 | EWTX | Edgewise Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $20.13 | +496,771 | 443,792 | -938% | +$10,000,000 | ||||||
2025-04-02 | MNPR | Monopar Therapeutics | Tactic Pharma LLC | 10% | S - Sale | $35.00 | -33,334 | 822,255 | -4% | -$1,166,690 | ||||||
2025-04-02 | BCYC | Bicycle Therapeutics Plc | Young Alethia | CFO | S - Sale | $8.02 | -215 | 45,390 | 0% | -$1,724 | ||||||
| M | 2025-04-02 | BCYC | Bicycle Therapeutics Plc | Skynner Michael | CTO | S - Sale | $7.72 | -1,852 | 121,870 | -1% | -$14,293 | |||||
| M | 2025-04-02 | BCYC | Bicycle Therapeutics Plc | Lee Kevin | CEO | S - Sale | $7.69 | -5,669 | 486,265 | -1% | -$43,612 | |||||
| M | 2025-04-02 | BCYC | Bicycle Therapeutics Plc | Milnes Alistair | COO | S - Sale | $7.76 | -2,171 | 97,617 | -2% | -$16,851 | |||||
| M | 2025-04-02 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $7.82 | -733 | 54,547 | -1% | -$5,735 | |||||
| M | 2025-04-02 | BCYC | Bicycle Therapeutics Plc | Thompson Travis Alvin | Chief Accounting Officer | S - Sale | $7.84 | -319 | 31,827 | -1% | -$2,500 | |||||
2025-04-02 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $46.95 | -897 | 75,997 | -1% | -$42,114 | ||||||
2025-04-04 | BFRG | Bullfrog Ai Holdings, Inc. | Singh Vininder | CEO, 10% | S - Sale | $1.30 | -5,895 | 2,342,446 | 0% | -$7,686 | ||||||
2025-04-03 | CYTK | Cytokinetics Inc | Harrington Robert Arthur | Dir | S - Sale | $39.43 | -450 | 14,658 | -3% | -$17,744 | ||||||
| M | 2025-03-03 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $5.18 | +74 | 32,392 | 0% | +$384 | |||||
| M | 2025-03-03 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $5.24 | +168 | 42,814 | 0% | +$881 | |||||
| M | 2025-03-03 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $5.24 | +168 | 5,698,906 | 0% | +$881 | |||||
| M | 2025-03-03 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $5.20 | +875 | 283,718 | 0% | +$4,548 | |||||
2025-04-02 | ERNA | Eterna Therapeutics Inc. | Cherington Charles | 10% | P - Purchase | $0.10 | +3,768,397 | 20,401,602 | +23% | +$394,174 | ||||||
2025-04-03 | APRE | Aprea Therapeutics, Inc. | Gilad Oren | Pres, CEO | P - Purchase | $1.84 | +5,500 | 347,420 | +2% | +$10,110 | ||||||
| M | 2025-04-01 | BFRG | Bullfrog Ai Holdings, Inc. | Singh Vininder | CEO, 10% | S - Sale | $1.51 | -44,105 | 2,348,341 | -2% | -$66,408 | |||||
2025-04-02 | CKPT | Checkpoint Therapeutics, Inc. | Oliviero James F III | CEO, Pres, Dir | S - Sale | $4.04 | -15,090 | 3,759,929 | 0% | -$60,964 | ||||||
2025-04-01 | CKPT | Checkpoint Therapeutics, Inc. | Gray William Garrett | CFO | S - Sale | $4.05 | -12,322 | 1,446,322 | -1% | -$49,904 | ||||||
| M | 2025-04-01 | ALMS | Alumis Inc. | Colowick Alan | Dir | P - Purchase | $7.04 | +18,404 | 18,404 | New | +$129,544 | |||||
2025-04-01 | ALMS | Alumis Inc. | Babler Martin | Pres, CEO, COB | P - Purchase | $6.44 | +15,650 | 106,454 | +17% | +$100,733 | ||||||
| D | 2025-04-01 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $15.76 | -55,771 | 116,704 | -32% | -$879,008 | |||||
2025-04-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | COB, CEO | S - Sale | $123.75 | -1,500 | 440,307 | 0% | -$185,625 | ||||||
| D | 2025-04-01 | BBIO | Bridgebio Pharma, Inc. | Ellis Andrea | Dir | S - Sale+OE | $34.05 | -30,000 | 12,000 | -71% | -$1,021,500 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $35.89 | -4,369 | 27,217 | -14% | -$156,821 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $35.89 | -5,808 | 476,046 | -1% | -$208,472 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $35.89 | -5,280 | 25,471 | -17% | -$189,520 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale+OE | $35.89 | -7,541 | 42,816 | -15% | -$270,677 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale+OE | $35.89 | -11,740 | 63,554 | -16% | -$421,396 | |||||
| D | 2025-04-01 | BGNE | Beigene, Ltd. | Wu Xiaobin | Pres, COO, GM China | S - Sale+OE | $281.40 | -51,921 | 1,192,433 | -4% | -$14,610,370 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Kathiresan Sekar | CEO | S - Sale+OE | $4.15 | -9,822 | 698,680 | -1% | -$40,761 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Nickerson Joan | Chief Administrative Officer | S - Sale+OE | $4.15 | -2,777 | 17,420 | -14% | -$11,525 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Ashe Andrew D. | See Remarks | S - Sale+OE | $4.15 | -2,681 | 348,828 | -1% | -$11,126 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Politi Jason | Chief Technical Ops. Officer | S - Sale+OE | $4.15 | -3,235 | 14,226 | -19% | -$13,425 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Dorval Allison | CFO | S - Sale+OE | $4.15 | -3,350 | 13,280 | -20% | -$13,903 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |